- Argonaut Manufacturing Services and Ensera have entered a strategic partnership to combine sterile fill-finish, device assembly, and packaging services for pharmaceutical customers.
- The companies said the collaboration is designed to simplify supply chains, reduce operational risk, and support faster development and manufacturing timelines for combination products.
Argonaut Manufacturing Services and Ensera have announced a strategic partnership that brings together sterile fill-finish, device assembly, and packaging capabilities for pharmaceutical and biotechnology customers. The companies said the collaboration is intended to align manufacturing activities across development and commercial programs while simplifying supply chain management for sponsors.
Under the agreement, Argonaut will provide aseptic fill-finish services for vials, syringes, and cartridges using Annex 1-compliant isolator filling lines, alongside analytical testing and stability studies. Ensera will provide final assembly of drug delivery devices, labeling, secondary packaging, kitting, serialization, sterilization management, and testing services for vials and drug delivery devices. The partnership combines capabilities across the contract manufacturing and CDMO value chain.
The companies said customers will have access to a streamlined quotation process covering services from both organizations before project initiation. Programs that engage both companies will also receive coordinated project management designed to align fill-finish and device assembly activities throughout development and manufacturing.
Argonaut has completed an audit of Ensera’s U.S. facility and approved the company as a critical supply chain partner. According to the companies, the arrangement supports quality alignment for clinical and commercial programs while addressing challenges including supply chain fragmentation, capacity constraints for mid-market programs, and pressure to accelerate timelines for specialty biologics and biosimilars.
“More than ever, our clients are focused on developing their products in conjunction with autoinjectors to improve accessibility for patients. While this is a commendable goal, it adds complexity to supply chains. This partnership with Ensera eases that burden for sponsors. Just as our clients are focused on improving the patient experience, Argonaut is focused on improving our clients’ experience.”
Rick Hancock, CEO of Argonaut
